Caroline Pinkney

Neura Health is a virtual neurology clinic for the 145 million Americans with neurological conditions; we have built the first national network of tele-neurologists. Our technology platform leverages smart triage, AI, and self-serve content to make diagnosis and treatment more efficient, while providing a proactive, patient-first solution that delivers empathetic, best-in-class neurological care to those living with disabling and often misunderstood diseases. With neurology as a top-five expense category for health plans and systems, the opportunity to drive cost savings plus deliver better patient outcomes is enormous. Neura Health treats migraine, headache, tremor, epilepsy, concussion, long-haul COVID, sleep, and patients with undiagnosed symptoms like pain, cognitive fog, numbness, and more. Neura has raised $10.3m in venture funding from the worlds top VC funds including Norwest Venture Partners, Next Play Ventures, Koch Disruptive Technologies, Pear VC, Index, Bessemer, and others. Staffed by top board-certified neurologists and sub-specialists, Neura Health connects patients with a neurologist video visit within a week, instead of months-long waitlists that local providers typically have. Patients receive a personalized treatment plan, a dedicated health coach, and a concierge team to manage their neurological disease. Neura Health’s quality care improves quality of life for people with neurological illness. Our clinical outcomes have been published in two peer-reviewed medical journals in 2022 and 2023.

At QurAlis, we are neuro pioneers on a quest to cure. We work with a relentless pursuit of knowledge, a precise attention to craft, and an optimistic mindset to discover and develop effective precision medicines that will forever alter the trajectory of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases. Founded by an internationally recognized team of neurodegenerative biologists from Harvard Medical School and Harvard University, QurAlis is advancing a pipeline with therapeutic candidates that target specific components of ALS and FTD pathology and defined patient populations based on both disease-causing genetic mutation(s) and clinical biomarkers.

ContinuumRx partners with healthcare systems and their providers to improve post acute-care coordination and care management, to help reduce gaps in patient care, to enhance the overall patient experience, and to help our provider partners improve their overall financial performance. We provide home infusion therapies and services to hundreds of patients each month and support them in their care and recovery through all phases of the healthcare continuum.

Neura Health is a virtual neurology clinic for the 145 million Americans with neurological conditions; we have built the first national network of tele-neurologists. Our technology platform leverages smart triage, AI, and self-serve content to make diagnosis and treatment more efficient, while providing a proactive, patient-first solution that delivers empathetic, best-in-class neurological care to those living with disabling and often misunderstood diseases. With neurology as a top-five expense category for health plans and systems, the opportunity to drive cost savings plus deliver better patient outcomes is enormous. Neura Health treats migraine, headache, tremor, epilepsy, concussion, long-haul COVID, sleep, and patients with undiagnosed symptoms like pain, cognitive fog, numbness, and more. Neura has raised $10.3m in venture funding from the worlds top VC funds including Norwest Venture Partners, Next Play Ventures, Koch Disruptive Technologies, Pear VC, Index, Bessemer, and others. Staffed by top board-certified neurologists and sub-specialists, Neura Health connects patients with a neurologist video visit within a week, instead of months-long waitlists that local providers typically have. Patients receive a personalized treatment plan, a dedicated health coach, and a concierge team to manage their neurological disease. Neura Health’s quality care improves quality of life for people with neurological illness. Our clinical outcomes have been published in two peer-reviewed medical journals in 2022 and 2023.

Here at Mitsui Global Investment, we get excited about cutting-edge technologies and scientific breakthroughs. Passionate entrepreneurs and forward-thinking investors inspire us, and we hope to do the same. We enjoy getting to know the teams we invest in and cherish opportunities to help out and provide value-add support. With the diversity and knowledge amassed through our years as a global enterprise, we bring a fresh eye to new business. We have been investing for over 20 years in venture opportunities with over 100 portfolio companies and 35 exits, and are currently seeking new investment opportunities. Please visit our website us if youd like to learn more.

At QurAlis, we are neuro pioneers on a quest to cure. We work with a relentless pursuit of knowledge, a precise attention to craft, and an optimistic mindset to discover and develop effective precision medicines that will forever alter the trajectory of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases. Founded by an internationally recognized team of neurodegenerative biologists from Harvard Medical School and Harvard University, QurAlis is advancing a pipeline with therapeutic candidates that target specific components of ALS and FTD pathology and defined patient populations based on both disease-causing genetic mutation(s) and clinical biomarkers.

ContinuumRx partners with healthcare systems and their providers to improve post acute-care coordination and care management, to help reduce gaps in patient care, to enhance the overall patient experience, and to help our provider partners improve their overall financial performance. We provide home infusion therapies and services to hundreds of patients each month and support them in their care and recovery through all phases of the healthcare continuum.